Big Data Genomics Trials 
AuroBlog - Aurous Healthcare Clinical Trials blog
MARCH 15, 2023
Some of the medical advances with the technology are genomics and epigenetics, Big Data, AI and ML which are allowing molecular […] Technology adoptions like artificial intelligence and machine learning are bringing in major transformation in the way a primary physician will extend treatment protocols.
ACRP blog
JUNE 7, 2023
If you hadn’t already noticed, the clinical research enterprise has well and truly entered the era of “big data,” artificial intelligence (AI), and machine learning. As a result, the time required to design, launch, and execute high-impact clinical trials is significantly reduced.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 8, 2022
The advent of biologic therapies in the 1970s along with the decoding of the human genome in 2003 heralded an explosion in pharmaceutical innovation. This has led to an increase in products coming to market with single‑arm Phase 3 data and surrogate endpoints or Phase 2b data, with planned confirmatory data to be released in the future.
XTalks
JULY 24, 2024
They also address diversity in clinical trials by supporting efforts to improve the representation of underrepresented patient populations. It provides 24/7 guidance, helping patients find clinical trials and facilitating communication with healthcare providers. Nanostics Inc.
Pharma Marketing Network
OCTOBER 14, 2024
The rise of big data analytics, artificial intelligence, and machine learning has revolutionized drug discovery, development, and marketing. With advancements in genomics and biotechnology, there is a move towards tailoring treatments to individual patients based on their genetic makeup.
Worldwide Clinical Trials
APRIL 7, 2025
Have you optimized your trial designs to employ precision medicine approaches for your novel solid tumor intervention? Integrate Biomarkers Where Possible Biomarker integration is crucial in solid tumor clinical trials, though more research is needed before fully validated assays become the norm across solid tumor indications.
pharmaphorum
SEPTEMBER 16, 2022
Essentially, the collaboration brought together both “the right expertise and the right technology”, opening up myriad possibilities for targeting GPCRs within the human genome. It also bodes well for improving clinical trial success rates. A notable issue with clinical trials is the homogeneity of the patient database.
Expert insights. Personalized for you.
100 
Let's personalize your content